| 25.9587 0 (0%) | 03-02 09:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.67 | 1-year : | 31.32 |
| Resists | First : | 26.26 | Second : | 26.81 |
| Pivot price | 26.19  |
|||
| Supports | First : | 25.36 | Second : | 21.1 |
| MAs | MA(5) : | 25.92 |
MA(20) : | 26.11 |
| MA(100) : | 24.97 |
MA(250) : | 23.22 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 29 |
D(3) : | 33.1 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 27.28 | Low : | 18.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ THNR ] has closed above bottom band by 28.0%. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26 - 26.13 | 26.13 - 26.24 |
| Low: | 25.48 - 25.63 | 25.63 - 25.76 |
| Close: | 25.72 - 25.96 | 25.96 - 26.18 |
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.
Wed, 04 Feb 2026
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook - TradingView
Mon, 12 Jan 2026
New Year, New Strategy: Navigating Weight Loss ETFs - ETF Trends
Mon, 29 Dec 2025
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug - Zacks Investment Research
Tue, 09 Dec 2025
Can You Buy Ozempic Stock in 2026? - The Motley Fool
Tue, 29 Jul 2025
Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs - ETF.com
Wed, 11 Jun 2025
Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected - The Daily Upside
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|